N‐Acyl amino acids and N‐acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets

The myriad functions of lipids as signalling molecules is one of the most interesting fields in contemporary pharmacology, with a host of compounds recognized as mediators of communication within and between cells. The N‐acyl conjugates of amino acids and neurotransmitters (NAANs) have recently come to prominence because of their potential roles in the nervous system, vasculature and the immune system. NAAN are compounds such as glycine, GABA or dopamine conjugated with long chain fatty acids. More than 70 endogenous NAAN have been reported although their physiological role remains uncertain, with various NAAN interacting with a low affinity at G protein coupled receptors (GPCR) and ion channels. Regardless of their potential physiological function, NAAN are of great interest to pharmacologists because of their potential as flexible tools to probe new sites on GPCRs, transporters and ion channels. NAANs are amphipathic molecules, with a wide variety of potential fatty acid and headgroup moieties, a combination which provides a rich source of potential ligands engaging novel binding sites and mechanisms for modulation of membrane proteins such as GPCRs, ion channels and transporters. The unique actions of subsets of NAAN on voltage‐gated calcium channels and glycine transporters indicate that the wide variety of NAAN may provide a readily exploitable resource for defining new pharmacological targets. Investigation of the physiological roles and pharmacological potential of these simple lipid conjugates is in its infancy, and we believe that there is much to be learnt from their careful study.

[1]  W. S. Ho,et al.  N‐arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium‐activated potassium channels , 2010, British journal of pharmacology.

[2]  J. Walker,et al.  Identification of endogenous acyl amino acids based on a targeted lipidomics approach1[S] , 2010, Journal of Lipid Research.

[3]  Robert M. Jones,et al.  N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. , 2010, Molecular endocrinology.

[4]  R. Vandenberg,et al.  Extracellular Loops 2 and 4 of GLYT2 Are Required for N-Arachidonylglycine Inhibition of Glycine Transport* , 2009, The Journal of Biological Chemistry.

[5]  A. Eschalier,et al.  T-Type Calcium Channel Inhibition Underlies the Analgesic Effects of the Endogenous Lipoamino Acids , 2009, The Journal of Neuroscience.

[6]  H. Bradshaw,et al.  The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  H. Bradshaw,et al.  The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways , 2009, BMC Biochemistry.

[8]  J. Caldwell,et al.  Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay , 2009, Journal of Biological Chemistry.

[9]  James I. Fells,et al.  Unique Ligand Selectivity of the GPR92/LPA5 Lysophosphatidate Receptor Indicates Role in Human Platelet Activation* , 2009, The Journal of Biological Chemistry.

[10]  M. Connor,et al.  Inhibition of human recombinant T‐type calcium channels by the endocannabinoid N‐arachidonoyl dopamine , 2009, British journal of pharmacology.

[11]  R. Ross The enigmatic pharmacology of GPR55. , 2009, Trends in pharmacological sciences.

[12]  D. Lovinger,et al.  The Endogenous Brain Constituent N-Arachidonoyl l-Serine Is an Activator of Large Conductance Ca2+-Activated K+ Channels , 2009, Journal of Pharmacology and Experimental Therapeutics.

[13]  Martin Jones,et al.  IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels , 2008, Nucleic Acids Res..

[14]  H. Bradshaw,et al.  Novel endogenous N-acyl glycines identification and characterization. , 2009, Vitamins and hormones.

[15]  J. Walker,et al.  Alcohol dehydrogenase-catalyzed in vitro oxidation of anandamide to N-arachidonoyl glycine, a lipid mediator: synthesis of N-acyl glycinals. , 2009, Bioorganic & medicinal chemistry letters.

[16]  H. Bradshaw,et al.  Microsomal omega-hydroxylated metabolites of N-arachidonoyl dopamine are active at recombinant human TRPV1 receptors. , 2009, Prostaglandins & other lipid mediators.

[17]  R. Vandenberg,et al.  Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. , 2008, Biochemical pharmacology.

[18]  S. Ikeda,et al.  N-arachidonoyl L-serine, a putative endocannabinoid, alters the activation of N-type Ca2+ channels in sympathetic neurons. , 2008, Journal of neurophysiology.

[19]  Min Goo Lee,et al.  Identification of Farnesyl Pyrophosphate and N-Arachidonylglycine as Endogenous Ligands for GPR92* , 2008, Journal of Biological Chemistry.

[20]  D. McHugh,et al.  N-Palmitoyl Glycine, a Novel Endogenous Lipid That Acts As a Modulator of Calcium Influx and Nitric Oxide Production in Sensory Neurons , 2008, Molecular Pharmacology.

[21]  M. Connor,et al.  Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol* , 2008, Journal of Biological Chemistry.

[22]  J. A. Lundbæk Lipid Bilayer–mediated Regulation of Ion Channel Function by Amphiphilic Drugs , 2008, The Journal of general physiology.

[23]  É. Szőke,et al.  Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. , 2008, Life sciences.

[24]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[25]  D. McHugh,et al.  Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2 , 2008, Molecular Pharmacology.

[26]  C. Vaughan,et al.  Actions of N-arachidonyl-glycine in a rat neuropathic pain model , 2008, Neuropharmacology.

[27]  W. Driscoll,et al.  Cytochrome c catalyzes the in vitro synthesis of arachidonoyl glycine. , 2008, Biochemical and biophysical research communications.

[28]  M. Martı́n,et al.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta , 2007, British journal of pharmacology.

[29]  S. O'Sullivan,et al.  Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.

[30]  S. Dowell,et al.  The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects , 2007, British journal of pharmacology.

[31]  D. Piomelli,et al.  A neuroscientist's guide to lipidomics , 2007, Nature Reviews Neuroscience.

[32]  Eric Gouaux,et al.  Antidepressant binding site in a bacterial homologue of neurotransmitter transporters , 2007, Nature.

[33]  J. W. Shaw,et al.  Potential anti-inflammatory actions of the elmiric (lipoamino) acids. , 2007, Bioorganic & medicinal chemistry.

[34]  V. Di Marzo,et al.  Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. , 2007, Experimental cell research.

[35]  Q. Pittman,et al.  Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret , 2007, The European journal of neuroscience.

[36]  G. Bernardi,et al.  N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors , 2007, Neuropsychopharmacology.

[37]  P. Lory,et al.  Chemical Determinants Involved in Anandamide-induced Inhibition of T-type Calcium Channels* , 2007, Journal of Biological Chemistry.

[38]  C. Vaughan,et al.  Actions of N-arachidonyl-glycine in a rat inflammatory pain model , 2007, Molecular pain.

[39]  R. Vandenberg,et al.  N‐Arachidonyl‐glycine inhibits the glycine transporter, GLYT2a , 2006, Journal of neurochemistry.

[40]  Atsushi Inoue,et al.  Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. , 2006, Biochemical and biophysical research communications.

[41]  H. Bradshaw,et al.  Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[42]  A. Saghatelian,et al.  A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. , 2006, Biochemistry.

[43]  M. Oz Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. , 2006, Pharmacology & therapeutics.

[44]  Y. Maor,et al.  N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Wolf,et al.  Receptors for Protons or Lipid Messengers or Both? , 2006, Journal of receptor and signal transduction research.

[46]  T. Bonnert,et al.  Functional characterisation of the S512Y mutant vanilloid human TRPV1 receptor , 2005, British journal of pharmacology.

[47]  A. Gerber,et al.  Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders , 2005, Journal of leukocyte biology.

[48]  D. Kendall,et al.  Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. , 2005, European journal of pharmacology.

[49]  A. Saghatelian,et al.  Assignment of endogenous substrates to enzymes by global metabolite profiling. , 2004, Biochemistry.

[50]  E. Butelman,et al.  Antiallodynic Effects of Loperamide and Fentanyl against Topical Capsaicin-Induced Allodynia in Unanesthetized Primates , 2004, Journal of Pharmacology and Experimental Therapeutics.

[51]  D. Merkler,et al.  Oleic acid derived metabolites in mouse neuroblastoma N18TG2 cells. , 2004, Biochemistry.

[52]  V. Di Marzo,et al.  Actions of two naturally occurring saturated N‐acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels , 2004, British journal of pharmacology.

[53]  R. Vandenberg,et al.  Zn2+ Inhibits Glycine Transport by Glycine Transporter Subtype 1b* , 2004, Journal of Biological Chemistry.

[54]  G. Czéh,et al.  Direct evidence for activation and desensitization of the capsaicin receptor by N-oleoyldopamine on TRPV1-transfected cell, line in gene deleted mice and in the rat , 2004, Neuroscience Letters.

[55]  S. Ikeda,et al.  Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. , 2004, Molecular pharmacology.

[56]  D. Kendall,et al.  Characterisation of the vasorelaxant properties of the novel endocannabinoid N‐arachidonoyl‐dopamine (NADA) , 2004, British journal of pharmacology.

[57]  M. Raisinghani,et al.  Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. , 2004, Journal of neurophysiology.

[58]  A. Minassi,et al.  A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. , 2004, Biochemical and biophysical research communications.

[59]  D. Lovinger,et al.  G Protein-coupled Endothelial Receptor for Atypical Cannabinoid Ligands Modulates a Ca2+-dependent K+ Current* , 2003, Journal of Biological Chemistry.

[60]  E. Butelman,et al.  Topical Capsaicin-Induced Allodynia in Unanesthetized Primates: Pharmacological Modulation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[61]  G. Ahern Activation of TRPV1 by the Satiety Factor Oleoylethanolamide* , 2003, Journal of Biological Chemistry.

[62]  B. Nilius,et al.  Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels , 2003, Nature.

[63]  L. Petrocellis,et al.  N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia* , 2003, The Journal of Biological Chemistry.

[64]  R. Vandenberg,et al.  Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a , 2003, Journal of neurochemistry.

[65]  J. Walker,et al.  Regulation of anandamide tissue levels by N-arachidonylglycine. , 2002, Biochemical pharmacology.

[66]  L. Marnett,et al.  Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. , 2002, Biochemical and biophysical research communications.

[67]  Pierangelo Geppetti,et al.  An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[68]  David Julius,et al.  Molecular Basis for Species-Specific Sensitivity to “Hot” Chili Peppers , 2002, Cell.

[69]  P. Lory,et al.  Direct inhibition of T‐type calcium channels by the endogenous cannabinoid anandamide , 2001, The EMBO journal.

[70]  J. Walker,et al.  Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain* , 2001, The Journal of Biological Chemistry.

[71]  A. Rittenhouse,et al.  Arachidonic acid reversibly enhances N-type calcium current at an extracellular site. , 2001, American journal of physiology. Cell physiology.

[72]  A. Rittenhouse,et al.  Arachidonic acid both inhibits and enhances whole cell calcium currents in rat sympathetic neurons. , 2001, American journal of physiology. Cell physiology.

[73]  T. Bisogno,et al.  Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. , 2001, Bioorganic & medicinal chemistry letters.

[74]  L. Petrocellis,et al.  N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. , 2000, The Biochemical journal.

[75]  T. Bisogno,et al.  Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.

[76]  B. Yagen,et al.  Oxidative metabolism of anandamide. , 2000, Prostaglandins & other lipid mediators.

[77]  T. Bonner,et al.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[78]  Z. Vogel,et al.  Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. , 1997, Journal of medicinal chemistry.

[79]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[80]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[81]  S. Bevan,et al.  Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region". , 1993, Journal of medicinal chemistry.

[82]  S. Bevan,et al.  Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 1. The aromatic "A-region". , 1993, Journal of medicinal chemistry.

[83]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[84]  U. Sankawa,et al.  Inhibition of in vitro prostaglandin and leukotriene biosyntheses by cinnamoyl-beta-phenethylamine and N-acyldopamine derivatives. , 1992, Chemical & pharmaceutical bulletin.